Depression is a common comorbidity in MS, which is associated with increased disease activity and disability. Dr Kaarina Kowalec (University of Manitoba, Canada) phrased the research question as follows: Is the cumulative genetic burden for depression associated with MS disease activity and disability worsening? To measure this genetic burden of depression, the researchers used the PGS, which reflects the number of inherited common genetic variants, weighted by their effect sizes. Using genetic variants, which do not change from birth, also means reverse causation as an explanation for any association between the PGS and outcomes can be excluded.
Dr Kolwalec and colleagues used a case-control study design, using samples from 3 cohorts from Canada (IMID study), USA (CombiRx trial), and Sweden (SMSReg) with extensive longitudinal phenotypes. They included 3,420 relapsing-onset MS cases of European genetic ancestry, with a median follow-up of 3â5 years.
âWe found that a higher depression PSG was associated with relapse risk,â Dr Kowalec said. âEvery 1-standard-deviation increase in the PSG was associated with a 23% increased hazard of relapse in the meta-analysisâ (incidence rate ratio 1.23; 95% CI 1.01â1.50). In the US cohort, which was the only clinical trial cohort, a higher depression genetic burden was also significantly associated with relapse risk (HR 2.20; 95% CI 1.35â3.60) and confirmed Expanded Disability Status Scale (EDSS) worsening (HR 1.51; 95% CI 1.03â2.22).
- Manouchehrinia A, et al. The association between depression polygenicity and disease activity and disability worsening in multiple sclerosis. Abstract O132, ECTRIMS 2024, 17â20 October 2024, Copenhagen, Denmark.
Medical writing support was provided by Michiel Tent
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« More comorbidity is associated with worse clinical outcomes in MS Next Article
Blood markers predict MS progression »
« More comorbidity is associated with worse clinical outcomes in MS Next Article
Blood markers predict MS progression »
Table of Contents: ECTRIMS 2024
Featured articles
Revised McDonald criteria allow earlier and more precise MS diagnosis
Tolebrutinib slows disability in non-relapsing secondary progressive MS
Online First
Revised McDonald criteria allow earlier and more precise MS diagnosis
Blood markers predict MS progression
High depression genetic burden associated with MS disease activity
More comorbidity is associated with worse clinical outcomes in MS
First-line moderate-efficacy DMTs show similar efficacy
Tolebrutinib slows disability in non-relapsing secondary progressive MS
Frexalimab shows favourable safety and efficacy in OLE
Transfer of ocrelizumab into breastmilk is negligible
Ineffective response to EBV in MS not seen in similar diseases
Encouraging real-world results of AHSCT to treat aggressive MS
Tolebrutinib slows disability worsening in relapsing MS
High-dose simvastatin does not slow disability progression in SPMS
Gut microbiota modulates inflammation and cortical damage
Related Articles
December 4, 2023
Prioritising high efficacy therapies in children with MS
September 10, 2020
Serum NfL predicts long-term clinical outcomes in MS
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com